- Home
- RIV vs XFOR Comparison
RIV vs XFOR Comparison
Compare RIV & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIV | XFOR |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | 45 |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 321.6M | 377.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RIV | XFOR |
|---|---|---|
| Price | $11.61 | $3.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 65.1K | ★ 1.0M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 12.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.93 | $1.35 |
| 52 Week High | $12.56 | $4.83 |
Technical Indicators
Market Signals| Indicator | RIV | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 53.19 | 47.07 |
| Support Level | $11.57 | $3.95 |
| Resistance Level | $11.84 | $4.38 |
| Average True Range (ATR) | 0.19 | 0.27 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 50.00 | 13.95 |
Price Performance
Historical ComparisonAbout RIV RiverNorth Opportunities Fund Inc.
Rivernorth Opportunities Fund Inc is a diversified, closed-end management investment company. The fund's investment objective is total return consisting of capital appreciation and current income.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.